Advertisement


Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease

ASCO20 Virtual Scientific Program

Advertisement

Peter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumor. The study found that about 50% of deaths can be avoided with longer imatinib treatment (Abstract 11503).



Related Videos

Issues in Oncology

Reshma Jagsi, MD, DPhil, and Narjust Duma, MD, on Diversity in Oncology: A Discussion of Evidence-Based Transformation

Reshma Jagsi, MD, DPhil, of the University of Michigan, and Narjust Duma, MD, of the University of Wisconsin Carbone Cancer Center, discuss the state of diversity in the hematology-oncology workforce, mechanisms that lead to inequities, promising interventions, and where the field should go next (Abstract 11000).

David C. Fajgenbaum, MD, MBA, on Chasing His Cure: A Physician Is Battling His Disease and Beating the Odds

David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castleman, a disease of the lymph nodes, his multiple near-death experiences, and the path that led him to develop a cooperative research effort making a difference for him and other patients with this idiopathic orphan illness.

Lymphoma
Immunotherapy

Nirav Niranjan Shah, MD, on DLBCL: Autologous Transplant vs CAR T-Cell Therapy

Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve only a PET/CT-positive partial remission, is appropriate in the era of CAR T-cell therapy (Abstract 8000).

Survivorship

Eric Zhou, PhD, on Insomnia in Young Cancer Survivors: Online Program May Improve Quality of Life

Eric Zhou, PhD, of Dana-Farber Cancer Institute, discusses an existing online program called SHUTi (Sleep Healthy Using the Internet), that he and his team adapted to the needs of adolescent and young adult cancer survivors. After six online cognitive behavior therapy sessions delivered over 8 weeks, the 22 patients in the study reported a significant reduction in insomnia severity, daytime sleepiness, and fatigue as well as an overall improvement in quality of life.

Welcome to This Year’s Meeting: A Message From ASCO President Howard A. Burris III, MD, FACP, FASCO

Howard A. Burris III, MD, FACP, FASCO, President of ASCO, talks about what to expect from this year’s ASCO20 Virtual Scientific Program and its many offerings.

Advertisement

Advertisement




Advertisement